For Investors

Investor Relations

Latest Press Releases

All Press Releases
Date Title
April 30, 2020
Novan Announces Receipt of Written Minutes from Type C Meeting with FDA Regarding Development of SB206
April 20, 2020
Novan Announces Comprehensive Evaluation of Strategic and Financial Alternatives
April 3, 2020
Novan Receives Verbal Guidance from FDA for SB206 and Announces Sato Program Advancement
March 26, 2020
Novan Announces Closing of $8.0 Million Registered Direct Offering Priced At-the-Market

Recent SEC Filings

All SEC Filings

Upcoming Events

More 
More events are coming soon.

Stock Information

more

Exchange
Volume
Today's Open
Previous Close

Data as of Jun 6, 2020 1:25 AM EDT

Data Provided by Refinitiv. Minimum 15 minutes delayed.

October 21, 2016
October 21, 2016

Corporate Governance

Click here to view our Corporate Governance information.

IR & Media Contact

  • Cole Ikkala
  • Director, Investor Relations, Communications & Business Development
  • cikkala@novan.com

Information Request

Click here to request information.

Presentation

More
May 28, 2020

Annual Report

More
June 24, 2019

Analyst Coverage

more
Firm Analyst
H.C. Wainwright & Co.
Oren Livnat
JMP Securities
Donald Ellis Pharm.D.

Novan, Inc. is followed by the analysts listed above. Please note that any opinions, estimates or forecasts regarding Novan, Inc.'s performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Novan, Inc. or its management. Novan, Inc. does not by its reference above or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations.

Transfer Agent

E-mail Alerts

  • Sign up here to get latest notifications whenever Novan inc. posts new information to the site.